solar lentigines post inflammatory hyperpigmentation solar lentigines post inflammatory hyperpigmentation
Conditions
Interventions
oral transamine 1500 mg,oral placebo
Experimental Drug,Placebo Comparator Other
Transamine,placebo
Sponsors
Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital
Division of Dermatology,
Department of Medicine,
Faculty of Medicine Ramathibodi Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Solar lentigine size > 5 mm Age between 18 to 60 years old
Exclusion criteria
Exclusion criteria: 1.patients treated solar lentigine with -topical medication within 7 days -dermabrasion within 2 weeks -chemical peels within 2 weeks -cryotherapy within 2 weeks -laser therapy within 4 weeks 2.allergy to transamine 3.on oral contraceptive pills, antiplatelet or anticoagulant drug 4.contraindication to tranexamic acid includings cardiovascular diseease, cerebrovascular disease, abnormal coagulation, pregnancy, lactation, acquired color blindness 5.history of keloid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy of transamine in prophylaxis of post inflammatory hyperpigmentation 0,2,4,6,12 week colorimeter, VISIA, digital photographs, dermoscope | — |
Secondary
| Measure | Time frame |
|---|---|
| safety of transamine 2,4,6,12 week questionnaire and physical examination ,risk of post inflammatory hyperpigmentation 0,4,6,12 week dermoscope | — |
Countries
Thailand
Contacts
Public ContactDuangrat Pruettivorawongse
Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital
Outcome results
None listed